Evidence mapPaperPMID 42490580Full record

ReviewJMIR diabetes2026

The Evolving Landscape of Continuous Glucose Monitoring Metrics in Type 1 Diabetes: Narrative Literature Review.

Eric Williams, Casey Rand, Alessandra Ayers, Cindy Ho, Ashley Dunova, David Klonoff, Juan Espinoza

Abstract readReview
In one paragraph

Review in JMIR diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eric WilliamsStanley Manne Children's Research Institute, Lurie Children's Hospital, 225 East Chicago Avenue, Chicago, IL, 60611, United States, 1 3122276090.ORCID http://orcid.org/0009-0002-8700-6722
Casey RandStanley Manne Children's Research Institute, Lurie Children's Hospital, 225 East Chicago Avenue, Chicago, IL, 60611, United States, 1 3122276090.ORCID http://orcid.org/0000-0003-1077-8978
Alessandra AyersDiabetes Technology Society, Burlingame, CA, United States.ORCID http://orcid.org/0009-0000-3054-3207
Cindy HoDiabetes Technology Society, Burlingame, CA, United States.ORCID http://orcid.org/0009-0008-3067-1004
Ashley DunovaDiabetes Technology Society, Burlingame, CA, United States.ORCID http://orcid.org/0000-0002-1478-7065
David KlonoffDiabetes Research Institute, Mills-Peninsula, San Mateo, CA, United States.ORCID http://orcid.org/0000-0001-6394-6862
Juan EspinozaStanley Manne Children's Research Institute, Lurie Children's Hospital, 225 East Chicago Avenue, Chicago, IL, 60611, United States, 1 3122276090.ORCID http://orcid.org/0000-0003-0513-588X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Continuous glucose monitoring (CGM) has transformed diabetes management and research by providing high-frequency data that address many of the limitations of hemoglobin A1c, enabling more precise clinical treatment targets and responsive trial endpoints. The richness and complexity of high-resolution time-series CGM data have spurred the development of numerous metrics for both clinical care and research applications. Beyond established metrics, there is a growing set of clinical, composite, and research-oriented measures that may support clinical decision support, intervention planning, risk stratification, and discovery-oriented research. This proliferation has created significant challenges in metric selection, interpretation, calculation, and standardization, particularly when metrics are applied across different devices, populations, software packages, and study designs. Objective: The objective is to map the current landscape of CGM metrics and address ongoing challenges in metric selection, clinical and research interpretation, and standardization. We further sought to distinguish between metrics primarily suited for routine clinical interpretation and those designed to explore more granular or multidimensional features of glycemia in research settings. Methods: We identified the literature focusing on the calculation, application, and interpretation of the following categories of CGM metrics: (1) standardized, (2) clinical, (3) emerging, and (4) composite. CGM metrics included in this study were identified from the 27 metrics included in the Diabetes Research Hub platform, additional published standardized and composite metrics, metrics used in established CGM analysis software, and emerging metrics identified during review. We narratively reviewed each metric's definitions, calculation methods, interpretation, clinical and research utility, and strengths and limitations. In total, 102 articles were reviewed, supporting the synthesis of 36 distinct CGM-derived metrics. Results: The review identifies a fundamental divide in the CGM metric landscape. Standardized and clinical metrics, including time in range, mean glucose, coefficient of variation, and similar, prioritize simplicity and actionability. These metrics facilitate rapid decision-making in clinical settings but potentially mask granular glycemic fluctuations, event patterns, and discordance between average glucose values and variability. Emerging and composite metrics offer deeper insights into glycemic patterns, risk, and variability. However, many rely on specialized software or complex formulas, lack standardized thresholds or clear relationships to clinical outcomes, and do not have consensus methods of calculation and interpretation, limiting their adoption and hindering cross-study comparison. Conclusions: While consensus exists for core clinical metrics, the lack of standardization for complex metrics hinders research replicability and clinical translation. Bridging this gap requires moving toward consensus metric definitions, open-science frameworks, and standardized code libraries. Metric selection should be guided by intended use. Clinical metrics should be well-established, interpretable, and actionable. Research metrics should be clearly described, reproducible, and linked to meaningful outcomes. This review provides a comprehensive resource for navigating the diverse spectrum of CGM metrics, clarifying their applications and limitations to support both research and clinical investigation.

Indexed as

CGMcontinuous glucose monitoringdiabetes mellitusdiabetes researchglycemic variabilityhemoglobin A1cnarrative reviewtime-series glucose data

Identifiers

PMID42490580
PMCPMC13394860

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.